Skip to content

Frank I. Tarazi

3 papers in the library · 77 citations · publishing 2021-2023

Papers

Sort Most recent Most cited

Risks and adverse events associated with the use of psychedelics

Psychedelics as Psychiatric Medications March 1, 2023 Joanna C. Neill, Mohammed Shahid, Rosalind Gittins et al.

Abstract Improved understanding of the potential risks and adverse effects of psychedelics is essential before psychedelic-assisted therapy is adopted into mainstream medicine. In spite of numerous recent clinical trials, gaps in knowledge remain. A comprehensive analysis of human receptor pharmacology is required to inform clinical dosing strategies and improve the understanding of drug-drug...

Invisible wounds: Suturing the gap between the neurobiology, conventional and emerging therapies for posttraumatic stress disorder.

European Neuropsychopharmacology August 2022 Xénia Gonda, Péter Döme, Berta Erdelyi-Hamza et al.

A sharp increase in the prevalence of neuropsychiatric disorders, including major depression, anxiety, substance use disorders and posttraumatic stress disorder (PTSD) has occurred due to the traumatic nature of the persisting COVID-19 global pandemic. PTSD is estimated to occur in up to 25% of individuals following exposure to acute or chronic trauma, and the pandemic has inflicted both forms...

Novel antidepressant drugs: Beyond monoamine targets

CNS Spectrums September 30, 2021 Xénia Gonda, Péter Döme, Joanna C. Neill et al. 77 citations

Abstract Treatment of major depressive disorder (MDD) including treatment-resistant depression (TRD) remains a major unmet need. Although there are several classes of dissimilar antidepressant drugs approved for MDD, the current drugs have either limited efficacy or are associated with undesirable side effects and withdrawal symptoms. The efficacy and side effects of antidepressant drugs are...

DOI: 10.1017/s1092852921000791 (opens in new tab) Major depressive disorder Antidepressant Monoamine neurotransmitter Tolerability +2